Overview

* Pulse Biosciences Q3 2025 revenue was $86 thousand, marking limited market release start

* GAAP net loss for Q3 widened to $19.4 mln from $12.7 mln last year

* Increased expenses due to expanding organization for clinical trials and commercialization

Result Drivers

* LIMITED MARKET RELEASE - Generated $86 thousand in revenue from the limited market release of nPulse Vybrance system

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$19.39

Income mln

Q3 -$20.37

Income mln

from

Operatio

ns

Analyst Coverage

* The one available analyst rating on the shares is "strong buy"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Pulse Biosciences Inc ( PLSE ) is $22.00, about 27% above its November 4 closing price of $16.06

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)